R80122 (0.3 mg/kg body weight), a new phosphodiesterase inhibitor, was tested in ten patients undergoing coronary artery bypass surgery. Haemodynamic measurements were made and hepatic blood flow assessed by the indocyanine green infusion method using liver vein catheterization. Cardiac index increased by 63% and systemic vascular resistance decreased by 47%. Hepatic blood flow and intestinal vascular resistance were not significantly affected; nor was hepatic oxygen consumption. It is concluded that R80122 is a highly cardioselective phosphodiesterase inhibitor and that the reduction in systemic vascular resistance by this drug is not an effect of extensive intestinal vasodilatation.
Le JemtelTH, KeungE, SonnenblickEH, RibnerHS, MatsumoM. Amrinone: A new nonglycosidic, nonadrenergic cardiotinic agent in the treatment of intractable myocardial failure in manCirculation1979; 59: 1098–104.
2.
WilmshurstPT, ThompsonDS, JenkinsBS, ColtartDJ, Webb-PeploeMM. Hemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. Br Heart J1983; 49: 77–82.
3.
BoldtJ, KlingD, SchuhmannE, DapperF, HempelmannG. Hemodynamic effects of the new phosphodiesterase inhibitor enoximone in patients undergoing heart surgery. Anaesthesist1989; 38: 238–44.
4.
CrawfordMH, RichardsKL, SodumsMT, KennedyGT. Positive inotropic and vasodilator effects of MDL 17, 043 in the treatment of congestive heart failure. Am J Cardiol1984; 53: 1051–3
5.
CrawfordMH. Intravenous use of enoximone. Am J Cardiol1987; 60: 42C.
6.
DageRC, RoebelLE, HsiehCP, WeinerDL, WoodwardJK. Cardiovascular properties of a new cardiotonic agent: Mdl 17, 043 (1, 3-dihydro-4-methyl-5-[4-(methylthio)-benzoyl]-2H-imidazol-2-one). J Cardiovasc Pharmacol1982; 4: 500–8.
7.
WeberKT, JanickiJS, JainMC. Enoximone (MDL 17, 043), a phosphodiesterase inhibitor, in the treatment of advanced unstable chronic heart failure. J Heart Transplant1986; 5: 105–7
8.
BradleySE. The hepatic circulation. In: HamiltonWF, DowP eds. Handbook of Physiology, Circulation II. Washington DC: The American Physiology Society, 1963: 1387–438
9.
LeevyCM, MendehallCL, LeskoW, HowardMK. Estimation of hepatic blood flow with indocyanine green. J Clin Invest1962; 41: 1169–79.
10.
HarrisAL, GrantAM, SilverPJ, EvansDB, AlousiAA. Differential vasorelaxant effects of milrinone and amrinone on contractile responses of canine coronary, cerebral and renal arteries. J Cardiovasc Pharmacol1988; 13: 238–44
11.
CodyRJ, KuboSH, CovitAB. Differential renal/systemic flow with chronic inotropic therapy. Impact on sodium excretion in heart failure. Clin Res1984; 32: 443A.
